Official websites use .gov
A
.gov website belongs to an official government
organization in the United States.
Secure .gov websites use HTTPS
A
lock (
) or https:// means you’ve safely connected to
the .gov website. Share sensitive information only on official,
secure websites.
The Unitaid-funded LONGEVITY project aims to develop long-acting formulations for malaria and latent tuberculosis (TB) prevention and a single-injection cure for hepatitis C virus (HCV) for low- and middle-income countries, as these diseases disproportionately affect children, poor and marginalized communities, people who use drugs, and people living with HIV.
The Viral Hepatitis National Progress Report provides information on progress in the implementation of recommended interventions and the impact these interventions are having on prevention of viral hepatitis transmission, disease, and associated mortality.
The resources presented here are based on data obtained from the Hepatitis B Foundation patient engagement survey in 2020. The survey was an anonymous and online and was offered globally for individuals living with chronic hepatitis B (CHB) and aged 18 years old and older. It received 1,707 responses from people living in 100 countries around the globe.
In 2019, NASTAD launched HepTAC, an online technical assistance (TA) and capacity building center for health department hepatitis programs. The primary goal of HepTAC is to build state and local technical expertise and enhance health department capacity to eliminate viral hepatitis. Direct technical assistance is provided primarily via the online platform using video conference technology to connect NASTAD Hepatitis team staff and its consultants to health department hepatitis staff across the county.
In recognition of Hepatitis Awareness Month, NACCHO is launching a new infographic characterizing viral hepatitis trends in the U.S., opportunities and barriers related to the prevention and elimination of viral hepatitis, and the role of local health departments (LHDs) in hepatitis prevention and elimination.
People experience harm in different, complex ways at both the structural and interpersonal levels. When people are criminalized because of illicit drug use, criminalized labor (like drug selling or sex work), or other stigmatized actions that are often survival behaviors, they are also more vulnerable to experiencing interpersonal violence.
As the United States heads into its third year in the fight against COVID-19, Americans have seen firsthand the importance of a robust and comprehensive response to public health emergencies and epidemics. The same is true for chronic viral hepatitis, a condition that impacts an estimated 3.3 million Americans. Without comprehensive plans to eliminate viral hepatitis, the US will fall short of reaching the World Health Organization’s (WHO’s) goal of fully eliminating the virus by 2030.
Hear from pharmacists across the country who are providing viral hepatitis care in unique settings. The webinar discusses opportunities and barriers to increasing pharmacist involvement in viral hepatitis care.
On Thursday, June 11, HepVu convened a webinar to discuss the impact of COVID-19 on harm reduction services, issues encountered on the ground, and potential solutions.
In collaboration with the National Viral Hepatitis Roundtable (NVHR), the Hepatitis Education Project (HEP), NASTAD, Hep B United, Hepatitis B Foundation, and National Association of County Health Officials (NACCHO), HepVu created a factsheet outlining the impact of the COVID-19 pandemic on viral hepatitis and the experiences of clinical providers, community-based organizations, and health departments during COVID-19.
